Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Vogl, K. Tenbrock, S. Ludwig, Nadja Leukert, C. Ehrhardt, M. Zoelen, W. Nacken, D. Foell, T. Poll, C. Sorg, J. Roth (2007)
Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shockNature Medicine, 13
M. Jonsson, N. Sundlisæter, H. Nordal, H. Hammer, A. Aga, Inge Olsen, K. Brokstad, D. Heijde, T. Kvien, B. Fevang, S. Lillegraven, E. Haavardsholm (2017)
Calprotectin as a marker of inflammation in patients with early rheumatoid arthritisAnnals of the Rheumatic Diseases, 76
Xun Gong, Shengqian Xu, Ying Wu, Canchen Ma, S. Qi, Wen Liu, Jian-hua Xu (2017)
Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese populationClinical Rheumatology, 36
T. Takeuchi (2017)
Biomarkers as a treatment guide in rheumatoid arthritis.Clinical immunology, 186
J. Smolen, F. Breedveld, G. Burmester, V. Bykerk, M. Dougados, P. Emery, T. Kvien, M. Navarro-Compán, S. Oliver, M. Schoels, M. Scholte-Voshaar, T. Stamm, M. Stoffer, T. Takeuchi, D. Aletaha, J. Andreu, M. Aringer, Martin Bergman, N. Betteridge, H. Bijlsma, H. Burkhardt, M. Cardiel, B. Combe, P. Durez, J. Fonseca, A. Gibofsky, J. Gómez-Reino, W. Graninger, P. Hannonen, B. Haraoui, M. Kouloumas, R. Landewé, E. Martı́n-Mola, P. Nash, M. Ostergaard, A. Östör, P. Richards, T. Sokka-Isler, C. Thorne, A. Tzioufas, R. Vollenhoven, M. Wit, D. Heijde (2015)
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnnals of the Rheumatic Diseases, 75
D. Aletaha, T. Neogi, A. Silman, J. Funovits, D. Felson, C. Bingham, Neal Birnbaum, G. Burmester, V. Bykerk, Marc Cohen, B. Combe, K. Costenbader, Maxime Dougados, Paul Emery, G. Ferraccioli, J. Hazes, Kathryn Hobbs, T. Huizinga, A. Kavanaugh, Jonathan Kay, T. Kvien, Timothy Laing, P. Mease, Henri Ménard, Larry Moreland, R. Naden, Theodore Pincus, Josef Smolen, E. Stanisławska-Biernat, D. Symmons, P. Tak, K. Upchurch, J. Vencovský, F. Wolfe, G. Hawker (2010)
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 69
C. Urban, David Ermert, M. Schmid, Ulrike Abu-Abed, C. Goosmann, W. Nacken, V. Brinkmann, P. Jungblut, A. Zychlinsky (2009)
Neutrophil Extracellular Traps Contain Calprotectin, a Cytosolic Protein Complex Involved in Host Defense against Candida albicansPLoS Pathogens, 5
J. Nies, A. Krabben, J. Schoones, T. Huizinga, M. Kloppenburg, A. Mil, T. Kvien (2013)
What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature reviewAnnals of the Rheumatic Diseases, 73
J. Hurnakova, H. Hulejová, J. Závada, M. Komarc, L. Cerezo, H. Mann, J. Vencovský, K. Pavelka, L. Šenolt (2018)
Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive proteinClinical Rheumatology, 37
S. Bae, Y. Lee (2017)
Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysisPostgraduate Medicine, 129
F. Ometto, L. Friso, D. Astorri, C. Botsios, B. Raffeiner, L. Punzi, A. Doria (2017)
Calprotectin in rheumatic diseasesExperimental Biology and Medicine, 242
I. Choi, D. Gerlag, M. Herenius, R. Thurlings, C. Wijbrandts, D. Foell, T. Vogl, J. Roth, P. Tak, D. Holzinger (2015)
MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.Annals of the rheumatic diseases, 74 3
H. Hammer, S. Ødeg̊ard, M. Fagerhol, R. Landewé, D. Heijde, T. Uhlig, P. Mowinckel, T. Kvien (2007)
Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritisAnnals of the Rheumatic Diseases, 66
M. García-Arias, D. Pascual‐Salcedo, S. Ramiro, M. Ueberschlag, T. Jermann, C. Cara, E. Martı́n-Mola, A. Balsa (2013)
Calprotectin in Rheumatoid ArthritisMolecular Diagnosis & Therapy, 17
J. Inciarte-Mundo, Maria Hernández, V. Ruiz-Esquide, Sonia Cabrera-Villalba, J. Ramírez, A. Cuervo, M. Pascal, J. Yagüe, J. Cañete, R. Sanmartí (2016)
Serum Calprotectin Versus Acute‐Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor InhibitorsArthritis Care & Research, 68
藤井隆夫 (2016)
Treating rheumatoid arthritis to the target―関節リウマチの治療戦略をここまで変えたものは何か―
H. Hammer, E. Haavardsholm, T. Kvien (2008)
Calprotectin (a major leucocyte protein) is associated with the levels of anti‐CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritisScandinavian Journal of Rheumatology, 37
H. Nordal, K. Brokstad, Magne Solheim, A. Halse, T. Kvien, H. Hammer (2017)
Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritisArthritis Research & Therapy, 19
A. Baillet, C. Trocmé, S. Berthier, M. Arlotto, L. Grange, J. Chenau, S. Quêtant, M. Sève, F. Berger, R. Juvin, F. Morel, P. Gaudin (2010)
Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases.Rheumatology, 49 4
C. Werning (1983)
[Rheumatoid arthritis].Medizinische Monatsschrift fur Pharmazeuten, 6 12
H. Hammer, S. Ødeg̊ard, S. Syversen, R. Landewé, D. Heijde, T. Uhlig, P. Mowinckel, T. Kvien (2008)
Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 69
J. Hurnakova, J. Závada, P. Hanova, H. Hulejová, M. Klein, H. Mann, O. Šléglová, M. Olejárová, Š. Forejtová, O. Růžičková, M. Komarc, J. Vencovský, K. Pavelka, L. Šenolt (2015)
Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritisArthritis Research & Therapy, 17
Anke Rammes, J. Roth, M. Goebeler, M. Klempt, M. Hartmann, C. Sorg (1997)
Myeloid-related Protein (MRP) 8 and MRP14, Calcium-binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-dependent Pathway*The Journal of Biological Chemistry, 272
D. Aletaha, T. Neogi, A. Silman, J. Funovits, D. Felson, C. Bingham, N. Birnbaum, G. Burmester, V. Bykerk, M. Cohen, B. Combe, K. Costenbader, M. Dougados, P. Emery, G. Ferraccioli, J. Hazes, K. Hobbs, T. Huizinga, A. Kavanaugh, J. Kay, T. Kvien, T. Laing, P. Mease, H. Ménard, L. Moreland, R. Naden, T. Pincus, J. Smolen, E. Stanisławska-Biernat, D. Symmons, P. Tak, K. Upchurch, J. Vencovský, F. Wolfe, G. Hawker (2010)
2010 Rheumatoid arthritis classifi cation criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
L. Hoovels, Julie Jacobs, B. Cruyssen, S. Bremt, P. Verschueren, X. Bossuyt (2018)
Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritisAnnals of the Rheumatic Diseases, 77
L. Cerezo, H. Mann, O. Pecha, L. Pleštilová, K. Pavelka, J. Vencovský, L. Šenolt (2011)
Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritisArthritis Research & Therapy, 13
J. Smolen, D. Aletaha, I. McInnes (2016)
Rheumatoid arthritisThe Lancet, 388
H. Hammer, M. Fagerhol, T. Wien, T. Kvien (2011)
The soluble biomarker calprotectin (a S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumabArthritis Research & Therapy, 13
H. Nordal, M. Fagerhol, A. Halse, H. Hammer (2018)
Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritisScandinavian Journal of Clinical and Laboratory Investigation, 78
T. Vogl, S. Ludwig, M. Goebeler, A. Strey, I. Thorey, R. Reichelt, D. Foell, V. Gerke, M. Manitz, W. Nacken, S. Werner, C. Sorg, J. Roth (2004)
MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes.Blood, 104 13
Mads Abildtrup, G. Kingsley, D. Scott (2015)
Calprotectin as a Biomarker for Rheumatoid Arthritis: A Systematic ReviewThe Journal of Rheumatology, 42
L. Pedersen, Erling Birkemose, C. Gils, S. Safi, M. Nybo (2018)
Sample Type and Storage Conditions Affect Calprotectin Measurements in Blood.The journal of applied laboratory medicine, 2 6
A. Finckh, D. Alpízar-Rodríguez, P. Roux‐Lombard (2017)
Value of Biomarkers in the Prevention of Rheumatoid ArthritisClinical Pharmacology & Therapeutics, 102
I. Korndörfer, F. Brueckner, A. Skerra (2007)
The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins.Journal of molecular biology, 370 5
AbstractBackgroundThere is a need for additional biomarkers to assist in the diagnosis and prognosis of rheumatoid arthritis (RA). The aim of our study was to evaluate the (pre-analytical, analytical and clinical) performance of serum calprotectin as a marker of inflammation in RA.MethodsThe study population included 463 rheumatologic patients (including 111 RA patients and 352 controls) who for the first time consulted a rheumatologist, 20 healthy controls and 27 patients with an infectious disease. Calprotectin was measured (using four different assays) in serum or in serum and EDTA plasma (healthy controls and infectious disease group). For rheumatologic patients, results for C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) were available.ResultsResults for blood calprotectin were assay- and matrix-dependent, with higher values found in serum than in plasma. Serum calprotectin was higher in RA patients than in rheumatologic diseased controls and in healthy controls. Serum calprotectin was lower in RA patients than in patients with an infectious disease. Serum calprotectin was associated with disease activity (DAS score). The area under the curve (AUC) to discriminate RA from controls was 0.756 for CRP, 0.714 for ESR and 0.726–0.783 for calprotectin.ConclusionsOur data document that calprotectin measurement is assay- and matrix-dependent. Serum calprotectin is associated with disease activity. Additional (prospective) studies are warranted to further evaluate the prognostic and diagnostic value of blood calprotectin measurements.
Clinical Chemistry and Laboratory Medicine (CCLM) – de Gruyter
Published: Dec 18, 2019
Keywords: biomarker; rheumatoid arthritis; serum calprotectin
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.